Application of yeast cell-wall derived from a potential probiotic yeast isolate as a controlled release agent in a triple-layer microcapsule with potent anti S. aureus activity

Abstract

Application of postbiotics derived from characterized probiotics (Probio) as efficient controlled release agents of the entrapped bioactives is a promising progress in microencapsulation strategies. In the present study, phylogenetic evolutionary analysis led to the identification of Pichia kudriavzevii as the potential Probio yeast isolated from fermented sprouted soybeans with 82.70 % survivability under simulated gastrointestinal (SGI) conditions and potent in vitro inhibitory activity against Staphylococcus aureus (88.21 %), which was significantly (p < 0.05) higher than those of the other foodborne bacteria tested. The yeast isolate also showed antifungal, antioxidant and suitable adhesion capabilities. Moreover, anti-ochratoxigenic activity of viable and heat-killed cells of the isolate was approved according to the HPLC-based analysis. In vivo safety of the isolate was also confirmed in accordance with the blood biochemistry parameters and liver enzymes activity of the fed-chicken compared to the control group. In vivo inhibitory activity of viable and heat-killed cells of the isolate against S. aureus was equal to 74.39 % and 89.71 %, respectively. Cross-linking of the yeast cell-wall derived from the isolate with the alginate-chitosan construct was also approved through FTIR and SEM analyses. In addition, antibacterial profile of the construct under SGI conditions confirmed targeted delivery and controlled release of the entrapped chitosan.